Advances in modification and delivery of nucleic acid drugs

Authors:

Abstract
Nucleic acid drugs are oligo RNA or oligo DNA in molecular structure that function at the genetic level. There are many types of nucleic acid drugs are available at present like aptamer, antisense oligonucleotide, mRNA, miRNA, siRNA, saRNA and so on. The nucleic acid drugs have high specificity, however, they face challenges in clinical applications, such as short half-life, poor stability, and susceptibility to endogenous nucleases. Their stability, physicochemical properties, affinity, and targeting can be improved through nucleic acid structure modification. Meanwhile, the nucleic acid carriers are conducive to drugs penetrating cell membrane to further enhance their stability and targeting properties, and facilitating their efficient intracellular escape to exert therapeutic effects. The delivery carriers including virus vectors, lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, protein carriers, and extracellular vesicles are commonly used currently. A combination of various modification method and drug delivery system is necessary to achieve better clinical therapeutic outcomes. This article reviews the research progress in characteristics, the structure modification methods, delivery systems and the further development of nucleic acid drugs, to provide a reference for the future clinical translational application of nucleic acid drugs.

This publication has 74 references indexed in Scilit: